Free Newsletter
Register for our Free Newsletters
Analysis, Inspection and Laboratory
Assisted/Independent Living
Clinical and Nursing Equipment
Design and Manufacture of Medical Equipment
Diagnostics Equipment, Monitoring and Test
Education, Training and Professional Services
Health Education and Patient Management
Health Estates Management
Healthcare Support and Information Services
Hygiene and Infection Control
IT and Communications in Healthcare
Medical Device Technology
Research and Development
Safety and Security
View All
Other Carouselweb publications
Carousel Web
Defense File
New Materials
Pro Health Zone
Pro Health Zone
Pro Security Zone
Web Lec
Pro Engineering Zone
Company Directory
5 Nachum Heth St., POB2059
Tirat Carmel
[t] +972 52 8515097
Collaborative agreement on exablate neuro technology
26 August, 2016
Insightec and Siemens have signed an agreement on the the development of integrated MRI and exablate neuro technology
ExAblate receives approval of Health Canada for uterine fibroids treatment
23 August, 2013
InSightec's ExAblate MR guided Focused Ultrasound therapy system receives approval of Health Canada for MRgFUS treatment of uterine fibroids and for pain palliation of bone metastases.
ExAblate receives extended CE Mark for benign and cancerous bone tumours
03 July, 2013
InSightec's ExAblate systems have received an extended European CE Mark for the local treatment of cancerous and benign primary and secondary bone tumours, including but not limited to multiple myeloma, bone metastases, osteoid osteoma as well as facet joint back pain.
InSightec's ExAblate Neuro to start pivotal Phase III trial for essential tremor treatment
20 February, 2013
InSightec receives FDA approval to begin the company's pivotal Phase III clinical trial for treatment of essential tremor using ExAblate Neuro.
InSightec completes additional financing of USD30.9m to develop focused ultrasound technology
10 December, 2012
InSightec completes the company's Series C financing totalling $30.9 million and includes an investment of $27.6 million by GE Healthcare and $3.3 million by other investors.
FDA approves new non-invasive, non-ionizing radiation therapy to treat pain from bone metastases
24 October, 2012
The US Food and Drug Administration (FDA) has approved InSightec's ExAblate MRI-guided focused ultrasound as a therapy to treat pain from bone metastases in patients who do not respond or cannot undergo radiation treatment for their pain.
US FDA allows InSightec to begin Phase I clinical trial for ExAblate Neuro system
22 August, 2012
InSightec receives approval from the US Food and Drug Administration (FDA) to begin a Phase I clinical trial evaluating the use of its ExAblate Neuro system for the treatment of patients with tremor dominant Parkinson's Disease.
Home I Editor's Blog I News by Zone I News by Date I News by Category I Special Reports I Directory I Events I Advertise I Submit Your News I About Us I Guides
   © 2012
Netgains Logo